Finasteride is a commonly used medication for treating benign prostatic hyperplasia and male androgenetic alopecia. It exerts its therapeutic effects by inhibiting 5α-reductase, thereby reducing the production of dihydrotestosterone. However, like all medications, it may also cause some side effects.
Regarding the incidence of side effects, data from different studies vary, but overall, they are not rare. In long-term clinical trials for patients with benign prostatic hyperplasia, the incidence of sexual side effects is approximately 1% to 10%. In lower-dose studies for hair loss, the incidence is typically lower, around 1% to 3%.
The most common side effects are related to sexual function. Decreased libido, erectile dysfunction, and reduced ejaculate volume are the most frequently reported, with reduced ejaculate volume having the relatively highest incidence. These side effects usually appear within months of starting the medication, and in most patients, the symptoms are mild to moderate.
Mood-related side effects have also drawn attention. A small number of patients may report depression, anxiety, or low mood. Population-based large-scale studies suggest an association between finasteride use and a slight increase in the risk of depression, but the causal relationship is not yet fully established and requires more high-quality evidence.
Gynecomastia is another potential side effect. Studies indicate an incidence rate of approximately 1% to 2%, presenting as breast tenderness or enlargement. In most cases, this condition is reversible and gradually resolves after discontinuation, though a small number of patients may require medication or surgical treatment.
In recent years, “post-finasteride syndrome” has been mentioned by some patients, referring to the persistence of side effects such as sexual dysfunction and depression after discontinuation of the drug. Currently, this syndrome is not fully recognized as an independent disease by mainstream medicine, but the U.S. FDA has added relevant warnings to the drug label. Existing evidence is primarily derived from case reports and retrospective studies, lacking large-scale controlled trials for validation.
Management strategies first emphasize adequate communication with a physician. When side effects occur, patients should not stop the medication on their own, as abrupt discontinuation may lead to a rebound of the underlying disease symptoms. The physician may recommend dose reduction, alternate-day dosing, or switching to another medication. If side effects significantly impact quality of life, discontinuation is usually considered, and in most cases, symptoms resolve within months.
Regarding the latest evidence, a large meta-analysis published in 2023, involving over 100,000 patients, confirmed that finasteride is associated with a significantly increased risk of sexual dysfunction, but the recovery rate after discontinuation exceeds 95%. Additionally, concerning the relationship between long-term use and prostate cancer risk, studies indicate that finasteride can reduce the incidence of low-grade prostate cancer, but its effect on high-grade cancer remains controversial and requires combined regular screening.
It is particularly important to emphasize that the occurrence of side effects varies significantly among individuals. Some people never experience any discomfort, while a small number may be very sensitive to the drug. Age, underlying health status, dosage, and duration of use may all influence the risk.
In summary, finasteride is an effective and generally safe medication, but patients should be fully informed of its potential side effects before use. If any discomfort occurs, timely discussion with a physician is the most reasonable approach.
(For reference only, not constituting medical advice.)